Clinical trial
Tipifarnib and Osimertinib in EGFR-mutated Non-Small Cell Lung Cancer
NCT05693090
Study timeline
Study start (estimated)2023-02-01Date precision: day
Registry last updated2023-03-06
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
NSCLCunresolved
Interventions
TipifarnibDRUG
OsimertinibDRUG · verified · RxNorm: osimertinib
Sponsors & collaborators
Kura Oncology, Inc.lead sponsor
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT05693090 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.